Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 10/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469696 | 0.84 | TTK (0.50) | TTKMAPKAPK5AURKAAURKB | |
| SCHEMBL25447222 | 0.82 | TTK (0.57) | TTKSRCMAPKAPK5AURKAAURKB | |
| SCHEMBL12409244 | 0.81 | TTK (0.68) | TTK | |
| SCHEMBL5411618 | 0.81 | FLT3 (0.56) | TTK | |
| SCHEMBL3467726 | 0.81 | TTK (0.57) | TTKSRCMAPKAPK5AURKAAURKB | |
| SCHEMBL12409307 | 0.81 | FYN (0.47) | TTKMAPKAPK5AURKABRAFAURKB | |
| SCHEMBL12288126 | 0.81 | RAF1 (0.54) | TTKSRCRAF1BRAFNPSR1 | |
| SCHEMBL30138985 | 0.80 | MAPKAPK5 (0.62) | TTKSRCMAPKAPK5AURKAAURKB | |
| SCHEMBL8240292 | 0.80 | AURKA (0.70) | TTKMAPKAPK5AURKAAURKBFYN | |
| SCHEMBL8247273 | 0.79 | AURKA (0.69) | TTKSRCMAPKAPK5AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | TTK 3239/4885SRC 2589/4885MAPKAPK5 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.